Enlivex Therapeutics
ENLV
ENLV
19 hedge funds and large institutions have $795K invested in Enlivex Therapeutics in 2023 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 7 reducing their positions, and 1 closing their positions.
Holders
19
Holders Change
–
Holders Change %
0%
% of All Funds
0.3%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
3
Reduced
7
Closed
1
Calls
$172K
Puts
$27K
Net Calls
+$145K
Net Calls Change
-$280K
Top Buyers
1 |
1
Morgan Stanley
New York
|
$115K |
2 |
![]()
2
JPMorgan Chase & Co
New York
|
$6.26K |
3 |
3
Renaissance Technologies
New York
|
$149K |
4 |
AAP
4
Arax Advisory Partners
Denver,
Colorado
|
$762 |
Top Sellers
1 |
1
UBS Group
Zurich,
Switzerland
|
$46.8K |
2 |
![]()
2
Group One Trading
Chicago,
Illinois
|
$2.89K |
3 |
3
Citadel Advisors
Miami,
Florida
|
$102K |
4 |
4
Goldman Sachs
New York
|
$29.7K |
5 |
SIGI
5
Susquehanna International Group (Ireland)
Dublin,
Ireland
|
$39.7K |